



US006440392B1

(12) **United States Patent**
Stern

(10) Patent No.: **US 6,440,392 B1**
(45) Date of Patent: **Aug. 27, 2002**

(54) **NASAL CALCITONIN FORMULATIONS**

(75) Inventor: **William Stern, Tenafly, NJ (US)**

(73) Assignee: **Unigene Laboratories, Inc., Fairfield, NJ (US)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/776,537**

(22) Filed: **Feb. 2, 2001**

Related U.S. Application Data

(60) Provisional application No. 60/180,241, filed on Feb. 4, 2000.

(51) Int. Cl.⁷ **A61K 9/12; A61K 9/00; A61K 38/23**

(52) U.S. Cl. **424/43; 424/45; 424/455; 514/2; 514/3; 514/12**

(58) Field of Search **424/43, 45, 455; 514/2, 3, 12**

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,059,587 A 10/1991 Yamamoto et al. 514/12

5,665,700 A * 9/1997 Cho et al. 514/2
6,087,338 A 7/2000 Veronesi et al. 514/21
6,149,893 A * 11/2000 Mardente et al. 424/45

OTHER PUBLICATIONS

Dua et al, International Journal of Pharmaceutics 147, 1997—pp. 233–242 “The influence of tonicity and viscosity on the intranasal absorption of salmon calcitonin in rabbits”.*

* cited by examiner

Primary Examiner—Jose' G. Dees

Assistant Examiner—Mina Haghighatian

(74) *Attorney, Agent, or Firm*—Ostrolenk, Faber, Gerb & Soffen, LLP

(57) **ABSTRACT**

A liquid pharmaceutical composition is disclosed comprising calcitonin or an acid addition salt thereof and citric acid or salt thereof in a concentration from about 10 mM to about 50 mM, said composition being in a form suitable for nasal administration.

23 Claims, No Drawings